GlassScriptPhysician profile
Michelle D Williams
NPI 1912151531
$158,183.26
in general payments reported to CMS, 2019-2025
54 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29K · 2022: $21K · 2023: $45K · 2024: $35K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $21K · Food and Beverage: $18K · Honoraria: $12K · Travel and Lodging: $2,871 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,053.75 |
| Consulting Fee | $21,089.50 |
| Food and Beverage | $18,363.67 |
| Honoraria | $12,027.00 |
| Travel and Lodging | $2,871.13 |
| Education | $137.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52,178.68 | 2021-2025 | |
| Axsome Therapeutics, INC. | $35,993.52 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $33,060.47 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $16,449.81 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $1,960.98 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,952.48 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,943.45 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,869.45 | 2021-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $1,792.60 | 2021-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $1,558.97 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Vanda Pharmaceuticals INC. | $1,154.84 | 2021-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $1,100.00 | 2021 | |
| Supernus Pharmaceuticals, INC. | $790.71 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $767.07 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $577.71 | 2022-2025 | Azstarys |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $553.83 | 2021-2025 | Trintellix, Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $462.15 | 2024-2025 | Cobenfy, Opdivo |
| Sunovion Pharmaceuticals INC. | $402.17 | 2021-2022 | |
| Tris Pharma INC | $399.45 | 2023-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $285.85 | 2021-2025 | Loreev Xr |
| Eisai INC. | $252.78 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $211.77 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $184.57 | 2023-2025 | Enhertu, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $173.93 | 2021-2023 | Belsomra |
| Janssen Biotech, INC. | $170.52 | 2023-2025 | Darzalex, Tecvayli, Erleada |
| Noven Therapeutics, LLC | $167.69 | 2021-2024 | Xelstrym |
| Glaxosmithkline, LLC. | $144.55 | 2023-2024 | Ojjaara, Jemperli |
| Avanir Pharmaceuticals, INC. | $134.01 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $130.96 | 2021-2022 | |
| Pfizer INC. | $118.96 | 2023-2025 | |
| Daiichi Sankyo INC. | $118.05 | 2023-2025 | Enhertu, Injectafer |
| Karyopharm Therapeutics INC. | $114.74 | 2023 | Xpovio |
| Incyte Corporation | $110.82 | 2023-2025 | Monjuvi, Monjuvi, Pemazyre |
| Collegium Pharmaceutical, INC. | $90.61 | 2025 | Jornay Pm |
| Seagen INC. | $85.40 | 2022-2023 | Tukysa, Padcev |
| Adlon Therapeutics L.P. | $82.82 | 2021 | |
| Iovance Biotherapeutics, INC. | $64.90 | 2025 | Amtagvi |
| Genzyme Corporation | $55.23 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $51.61 | 2022 | |
| Aytu Biopharma, INC. | $46.22 | 2021 | |
| Genentech USA, INC. | $40.85 | 2025 | Venclexta, Polivy |
| Recordati_rare_diseases_inc. | $39.02 | 2023 | Sylvant |
| Novartis Pharmaceuticals Corporation | $37.99 | 2024-2025 | |
| Exelixis INC. | $36.09 | 2025 | Cabometyx |
| Immunocore Limited | $34.55 | 2024 | Kimmtrak |
| Pharmaessentia USA Corporation | $32.97 | 2025 | Besremi |
| Amgen INC. | $31.67 | 2023 | Evenity, Prolia |
| Celgene Corporation | $27.67 | 2023 | Reblozyl |
| Lilly USA, LLC | $27.57 | 2024 | Verzenio, Jaypirca |
| Mirati Therapeutics, INC. | $23.57 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $23.03 | 2025 | |
| Indivior INC. | $22.50 | 2024 | Perseris |
| Array Biopharma INC | $21.86 | 2025 | Mektovi, Braftovi, Tukysa |
| Acadia Pharmaceuticals INC | $19.59 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.